keyword
MENU ▼
Read by QxMD icon Read
search

Antidepressants schizophrenia

keyword
https://www.readbyqxmd.com/read/27889833/factors-associated-with-expression-of-extrapyramidal-symptoms-in-users-of-atypical-antipsychotics
#1
Susana Barbosa Ribeiro, Aurigena Antunes de Araújo, Caroline Addison Xavier Medeiros, Katarina Melo Chaves, Maria do Socorro Costa Feitosa Alves, Antonio Gouveia Oliveira, Rand Randall Martins
PURPOSE: The aim of this study was to investigate factors associated with the occurrence of extrapyramidal symptoms (EPS) in users of second-generation antipsychotics (SGA). METHODS: Observational cross-sectional study based on a random sample of subjects from three outpatient clinics. Inclusion criteria were age between 18 and 65 years, of both genders, with a diagnosis of schizophrenia and under the use of a single SGA agent. Subjects who had received i.m. long-acting antipsychotics in the past were excluded...
November 26, 2016: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27872261/comorbid-diabetes-and-depression-in-a-national-sample-of-adults-with-psychosis
#2
Debra L Foley, Andrew Mackinnon, Vera A Morgan, David J Castle, Anna Waterreus, Cherrie A Galletly
OBJECTIVE: People with psychosis have an elevated risk of depression and diabetes but no large-scale study has characterized their relationship. We aimed to assess this association and to evaluate possible explanatory factors. METHODS: Analysis of cross-sectional data from a national sample of 1155 people with psychosis who gave a fasting blood sample and could be tested for diabetes mellitus. The association between current diabetes mellitus and current depression was estimated using logistic regression, adjusted for age, sex and current psychotropic medication...
November 21, 2016: Schizophrenia Bulletin
https://www.readbyqxmd.com/read/27855437/the-relevance-of-negative-symptoms-in-schizophrenia-and-how-to-treat-them-with-psychopharmaceuticals
#3
Hans-Jürgen Möller
Negative symptoms are highly prevalent in the acute episode and long-term course of schizophrenia. They are often persistent and tend to chronicity. They have an important negative impact on different dimensions of outcome and therefore require careful diagnosis and treatment. However, the evidence for the available psychopharmacological treatments is still not satisfactory and further research is needed. Antipsychotics, especially some second-generation antipsychotics, are the primary treatment of choice, particularly for negative symptoms in the acute episode...
December 2016: Psychiatria Danubina
https://www.readbyqxmd.com/read/27846049/agomelatine-for-the-treatment-of-major-depressive-episodes-in-schizophrenia-spectrum-disorders-an-open-prospective-proof-of-concept-study
#4
Susanne Englisch, Hanna Sophie Jung, Antje Lewien, Anna Becker, Ulrike Nowak, Hanna Braun, Jascha Thiem, Sarah Eisenacher, Andreas Meyer-Lindenberg, Mathias Zink
BACKGROUND: Depressive episodes in schizophrenia constitute a major clinical problem, and treatment success is often limited by treatment-emergent side effects. Agomelatine, an agonist at melatonergic MT1/MT2 receptors and 5-HT2C receptor antagonist, is a new antidepressant with a novel mode of action which constitutes a potential therapeutic option for depression in schizophrenia. METHODS: Twenty-seven patients with lifetime diagnoses within the schizophrenia spectrum and comorbid depression were treated with agomelatine in addition to stable doses of antipsychotic agents...
October 29, 2016: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27845315/-agomelatine-valdoxan-in-treatment-of-endogenous-depression-in-day-patient-department
#5
E V Chernova, O V Kozhechkina, A Yu Ter-Israelyan, V E Medvedev
AIM: Naturalistic psychopharmacological study of efficacy and tolerability of agomelatine (valdoxan) in treatment of endogenous depressions (in the framework of schizophrenia, schizoaffective and bipolar disorder) in day patient department. MATERIAL AND METHODS: Study sample consisted of 37 patient (59.4% female, mean age 41.6±3.7 years). RESULTS AND CONCLUSION: CDS total score significantly reduced after 8 weeks of treatment 44.9% compared to baseline (р<0...
2016: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/27827340/no-association-between-current-depression-and-latent-toxoplasmosis-in-adults
#6
Shawn D Gale, Andrew N Berrett, Bruce Brown, Lance D Erickson, Dawson W Hedges
Changes in behaviour and cognition have been associated with latent infection from the apicomplexan protozoan Toxoplasma gondii (Nicolle et Manceaux, 1908) in both animal and human studies. Further, neuropsychiatric disorders such as schizophrenia have also been associated with latent toxoplasmosis. Previously, we found no association between T. gondii immunoglobulin G antibody (IgG) seropositivity and depression in human adults between the ages of 20 and 39 years (n = 1 846) in a sample representative of the United States collected by the Centers for Disease Control as part of a National Health and Nutrition Examination Survey (NHANES) from three datasets collected between 1999-2004...
September 26, 2016: Folia Parasitologica
https://www.readbyqxmd.com/read/27825780/demographic-and-clinical-differences-between-early-and-late-onset-bipolar-disorders-in-a-multicenter-study-in-china
#7
Ling Zhang, Hai-Chen Yang, Xiu-Feng Xu, Yi-Ru Fang, Xin Yu, Qing-Rong Tan, Hui-Chun Li, Gabor S Ungvari, Chee H Ng, Gang Wang, Yu-Tao Xiang
Little is known about the demographic and clinical differences between early-onset (EOB) and late-onset bipolar disorders (LOB) in Chinese patients. This multi-center study examined the demographic and clinical characteristics of EOB (≤21 years) and LOB (>21 years) in China. A consecutively recruited sample of 555 patients with bipolar disorder (BD) from 7 psychiatric hospitals and general hospital psychiatric units across China was examined. Patients' demographic and clinical characteristics were collected using a standardized protocol and data collection procedure...
October 30, 2016: Psychiatry Research
https://www.readbyqxmd.com/read/27805978/agomelatine-for-the-treatment-of-major-depressive-episodes-in-schizophrenia-spectrum-disorders-an-open-prospective-proof-of-concept-study
#8
Susanne Englisch, Hanna Sophie Jung, Antje Lewien, Anna Becker, Ulrike Nowak, Hanna Braun, Jascha Thiem, Sarah Eisenacher, Andreas Meyer-Lindenberg, Mathias Zink
BACKGROUND: Depressive episodes in schizophrenia constitute a major clinical problem, and treatment success is often limited by treatment-emergent side effects. Agomelatine, an agonist at melatonergic MT1/MT2 receptors and 5-HT2C receptor antagonist, is a new antidepressant with a novel mode of action which constitutes a potential therapeutic option for depression in schizophrenia. METHODS: Twenty-seven patients with lifetime diagnoses within the schizophrenia spectrum and comorbid depression were treated with agomelatine in addition to stable doses of antipsychotic agents...
December 2016: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27796754/ketamine-self-administration-reduces-the-homeostasis-of-the-glutamate-synapse-in-the-rat-brain
#9
Lucia Caffino, Alessandro Piva, Giuseppe Giannotti, Marzia Di Chio, Francesca Mottarlini, Marco Venniro, David T Yew, Cristiano Chiamulera, Fabio Fumagalli
Ketamine is a non-competitive antagonist of the NMDA glutamate receptor with psychotomimetic and reinforcing properties, although recent work has pointed out its antidepressant action following acute exposure. Our aim was to investigate the expression of crucial components of the glutamate synapse following chronic ketamine self-administration (S/A), focusing our attention on medial prefrontal cortex (mPFC) and hippocampus (Hip), two brain regions involved in compulsive drug-seeking and drug-related cognitive disorders...
October 29, 2016: Molecular Neurobiology
https://www.readbyqxmd.com/read/27774073/effects-of-music-therapy-on-drug-therapy-of-adult-psychiatric-outpatients-a-pilot-randomized-controlled-study
#10
Mario Degli Stefani, Michele Biasutti
Objective: Framed in the patients' engagement perspective, the current study aims to determine the effects of group music therapy in addition to drug care in comparison with drug care in addition to other non-expressive group activities in the treatment of psychiatric outpatients. Method: Participants (n = 27) with ICD-10 diagnoses of F20 (schizophrenia), F25 (schizoaffective disorders), F31 (bipolar affective disorder), F32 (depressive episode), and F60 (specific personality disorders) were randomized to receive group music therapy plus standard care (48 weekly sessions of 2 h) or standard care only...
2016: Frontiers in Psychology
https://www.readbyqxmd.com/read/27757131/decreased-plasma-bdnf-levels-of-patients-with-somatization-disorder
#11
Nam-In Kang, Jong-Il Park, Yong-Ku Kim, Jong-Chul Yang
OBJECTIVE: Brain-derived neurotrophic factor (BDNF), one of the most abundant and important neurotrophins, is known to be involved in the development, survival, maintenance, and plasticity of neurons in the nervous system. Some studies have suggested that BDNF may play a role in the pathophysiology of several psychiatric illnesses such as depression and schizophrenia. Similarly, it is likely that the alteration of BDNF may be associated with the neuro-modulation that contributes to the development of somatization disorder...
September 2016: Psychiatry Investigation
https://www.readbyqxmd.com/read/27701952/add-on-mirtazapine-improves-orgasmic-functioning-in-patients-with-schizophrenia-treated-with-first-generation-antipsychotics
#12
Viacheslav Terevnikov, Jan-Henry Stenberg, Jari Tiihonen, Mark Burkin, Grigori Joffe
AIM: Sexual dysfunction, common in schizophrenia, may be further exaggerated by antipsychotics, especially those of First Generation (FGAs), and antidepressants, such as Selective Serotonin Reuptake Inhibitors (SSRs). Mirtazapine, an antidepressant characterized by its different action mechanism compared with that of the majority of other antidepressants, may improve SSRI-induced sexual dysfunction in patients with depression. It is unknown, however, whether mirtazapine improves sexual functioning in schizophrenia...
October 5, 2016: Nordic Journal of Psychiatry
https://www.readbyqxmd.com/read/27658832/treatment-patterns-of-schizophrenia-based-on-the-data-from-seven-central-and-eastern-european-countries
#13
Monika Szkultecka-Dębek, Katarzyna Miernik, Jarosław Stelmachowski, Miro Jakovljević, Vlado Jukić, Kaire Aadamsoo, Sven Janno, István Bitter, Judit Tolna, Marek Jarema, Slobodan Jankovic, Jan Pecenak, Livia Vavrusova, Rok Tavčar, Jacek Walczak, Darren Talbot, Joanna Augustyńska
OBJECTIVE: The aim is to analyze how schizophrenia is pharmacologically treated in seven CEE countries: Croatia, Estonia, Hungary, Poland, Serbia, Slovakia and Slovenia. METHODS: Psychiatrists from selected centers in each of participating countries were asked to complete a pre-defined questionnaire on their current clinical practice. Information on protocols and resource utilization in schizophrenia treatment was included and derived from randomly selected patient medical records...
September 2016: Psychiatria Danubina
https://www.readbyqxmd.com/read/27638627/the-risk-of-thromboembolism-in-users-of-antidepressants-and-antipsychotics
#14
Kasper Adelborg, Jens Sundbøll, Poul Videbech, Erik L Grove
Arterial and venous thromboembolism are common causes of morbidity and mortality in the Western world. Mental disorders are also highly prevalent with a lifetime risk of experiencing any psychiatric disease ranging between 32 % and 37 %. Depression and schizophrenia may increase the risk of thromboembolism through genetic, behavioral, and biological mechanisms. Treatment of psychiatric patients with psychotropic drugs is imperative to improve quality of life and to reduce morbidity and mortality. However, studies have shown that psychotropic drugs themselves may modify the risk of arterial and venous thromboembolism, which should be taken into consideration when using these drugs in clinical practice...
September 17, 2016: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/27593442/understanding-the-impact-of-5-httlpr-antidepressants-and-acute-tryptophan-depletion-on-brain-activation-during-facial-emotion-processing-a-review-of-the-imaging-literature
#15
REVIEW
Kyeon Raab, Peter Kirsch, Daniela Mier
Detecting and evaluating emotional information from facial expressions as a basis for behavioural adaption belong to the core social-cognitive abilities of mankind. Dysfunctions in emotional face processing are observed in several major psychiatric disorders like depression and schizophrenia. In search for psychiatric disease biomarkers using the imaging genetics approach, serotonergic gene polymorphisms have been associated with altered brain circuit activation during emotional face processing. Especially the 5-HTTLPR gene polymorphism has been extensively investigated in association with emotion regulation processes...
September 1, 2016: Neuroscience and Biobehavioral Reviews
https://www.readbyqxmd.com/read/27552677/potential-drug-drug-interaction-in-mexican-patients-with-schizophrenia
#16
María Conchita Ocaña-Zurita, Isela E Juárez-Rojop, Alma Genis, Carlos Alfonso Tovilla-Zárate, Thelma Beatriz González-Castro, María Lilia López-Narváez, María Elena de la O de la O, Humberto Nicolini
OBJECTIVE: The aim of this study was to observe potential drug-drug interactions in the medication of Mexican schizophrenic patients. METHODS: We performed a retrospective and cross-sectional study that was carried out in a psychiatric clinic. Only the prescriptions of patients with schizophrenia whose diagnoses were based on the DSM-IV instrument were included in this study. The Drug Interactions Checker software ( http://www.drugs.com/drug_interactions.html ) was used in this study to analyse potential drug-drug interactions...
November 2016: International Journal of Psychiatry in Clinical Practice
https://www.readbyqxmd.com/read/27549375/pharmacological-treatment-of-cannabis-related-disorders-a-narrative-review
#17
David A Gorelick
BACKGROUND: Cannabis is the most widely used illicit psychoactive substance world-wide, yet no medication is approved for the treatment of intoxication, withdrawal, or cannabis use disorder (CUD). OBJECTIVE: To comprehensively review the current state of knowledge. METHOD: Search of the PubMed electronic data base and review of reference lists of relevant articles to identify controlled clinical trials of pharmacological treatment. RESULTS: The search identified 4 trials for specific intoxication symptoms (none for global intoxication), 7 trials for withdrawal, and 12 phase II trials for CUD...
August 22, 2016: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/27545441/impact-of-dnmt1-and-dnmt3a-forebrain-knockout-on-depressive-and-anxiety-like-behavior-in-mice
#18
Michael J Morris, Elisa S Na, Anita E Autry, Lisa M Monteggia
DNA methylation has been shown to impact certain forms of synaptic and behavioral plasticity that have been implicated in the development in psychiatric disorders. DNA methylation is catalyzed by DNA methyltransferase (DNMT) enzymes that continue to be expressed in postmitotic neurons in the forebrain. Using a conditional forebrain knockout of DNMT1 or DNMT3a we assessed the role of these DNMTs in anxiety and depressive-like behavior in mice using an array of behavioral testing paradigms. Forebrain deletion of DNMT1 had anxiolytic and antidepressant-like properties as assessed by elevated plus maze, novelty suppressed feeding, forced swim, and social interaction tests...
November 2016: Neurobiology of Learning and Memory
https://www.readbyqxmd.com/read/27539712/perspectives-in-designing-multifunctional-molecules-in-antipsychotic-drug-discovery
#19
Andrea Milelli, Eleonora Turrini, Elena Catanzaro, Francesca Maffei, Carmela Fimognari
Preclinical Research A novel and promising approach to overcome the limits of single-target therapy is represented by the multitarget approach. This strategy aims to simultaneously modulate several targets involved in the pathophysiology of a multifactorial disease, with the potential to enhance therapeutic effectiveness and improve drug safety. Although there has been a marked growth in the design of multitarget drugs (MTDs) in the last years in the context of anti-Alzheimer and anti-cancer drug discovery, a parallel expansion was not observed in antipsychotic drugs, even that for psychiatric disorders there is a cogent medical need for new treatments...
August 19, 2016: Drug Development Research
https://www.readbyqxmd.com/read/27539538/antidepressant-action-on-mitochondrial-dysfunction-in-psychiatric-disorders
#20
REVIEW
Miroslav Adzic, Zeljka Brkic, Sonja Bulajic, Milos Mitic, Marija B Radojcic
Preclinical Research Mitochondria are cell organelles crucial to the production of cellular energy. Several lines of evidence have indicated that mitochondrial dysfunction could be related to the pathophysiology of CNS diseases including bipolar disorder, major depressive disorder, and schizophrenia. These changes include impaired energy metabolism in the brain, co-morbidity with mitochondrial diseases, the effects of psychotropics on mitochondrial function, increased mitochondrial DNA (mtDNA) deletion in the brain, and association with mtDNA polymorphisms...
November 2016: Drug Development Research
keyword
keyword
51990
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"